Investor Home

Investor Home

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ... More >>

Recent Newsmore >
04/19/17
Nabriva Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., April 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Deutsche Bank 42nd Annual Health Ca... 
04/17/17
Nabriva Announces the Proposed Redomicile of its Holding Company from Austria to Ireland, by means of an Exchange Offer
VIENNA, Austria, April 17, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV) (“Nabriva AG”) announced that its supervisory board and management board approved the relocation of the holding company of Nabriva AG and its subsidiaries (“Nabriva Group”) from Austria to Ireland (the “Redomiciliation Transaction”). The Redomiciliation Transaction will be effected by the exchange of American depositary shares (“Nabriva AG ADSs”) and shares (the “Exchange Offer”) of Nabriva AG for shares ... 
04/13/17
Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin
Nine abstracts support potential for lefamulin as a first-line, empiric treatment for patients with community-acquired bacterial pneumonia VIENNA, Austria and KING OF PRUSSIA, Pa., April 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will present data a... 
Upcoming Eventsmore >
DateTitleRemind
Me
Prior to
Event
05/03/17 4:10 p.m. ET
Nabriva at the Deutsche Bank Health Care Conference
days
Enter your e-mail address 
Data provided by Nasdaq. Minimum 15 minutes delayed.